Stryker enters the final day of September with a paradox at its core: the stock is up 1.3% on the week to $278.77, yet analysts have spent the past three weeks slashing price targets. The gap between where the shares trade and where the Street thinks they belong remains wide, but confidence in the destination is clearly fading.
The analyst picture is the most striking feature of the current setup. Every recent action has been a target reduction. Stifel cut to $330 from $360 this morning while keeping its Buy. TD Cowen trimmed to $298 from $355 last week, maintaining Hold. Citigroup and Wells Fargo both cut earlier in September, the latter taking its Overweight target from $418 all the way down to $348. The mean target across the Street is $367.80, implying roughly 32% upside from current levels. That headline number looks appealing, but the direction of travel matters: targets have come down sharply and broadly since the July 30 earnings report, when the stock fell 7.5% in a single session and finished the following week down 4.2%. The bear case is concrete. Peripheral Vascular supply problems are running the franchise at roughly minus 5% year-on-year in the third quarter. Gross margins are under pressure. And a cyberattack is creating a second-half recovery story that execution has to deliver. Wolfe Research downgraded outright to Peer Perform in August. The bulls, by contrast, point to diversification across orthopedics, MedSurg and capital equipment, a strong order book, and trauma and extremities growing faster than market. The next print on October 30 will be the first real test of whether the recovery narrative holds.
The lending market adds almost nothing to that debate this week. Short interest is genuinely modest at 1.9% of free float, up about 12% on the week in share terms, but coming off lows and still well within normal territory for a large-cap medical device name. Cost to borrow has fallen nearly 38% over the past week to just 0.36%, trivial for any short seller. Availability is extraordinarily loose, with roughly 178 million shares available to borrow against a short position of 7.4 million, borrow is not a constraint here in any meaningful sense. The ORTEX short score of 32.8 sits in the 60th percentile on the short-score rank, unremarkable. Options traders have become somewhat more defensive this week, with the put/call ratio at 0.68, about 1.3 standard deviations above its 20-day average of 0.59, though still well below the 52-week high of 0.96. The options shift looks like a modest hedge into earnings rather than a directional conviction trade.
The ownership register carries one genuinely notable item: Ronda Stryker, a director and one of the company's largest named holders, filed a Schedule 13D/A in April, placing her on the activist register. She now holds approximately 4.0% of shares as last disclosed. In August she sold around 15,000 shares across multiple transactions on August 19 at prices ranging from $332 to $343, totalling roughly $6.1 million. That selling occurred at prices meaningfully above where the stock trades today. Net insider activity over the past 90 days is negative at roughly minus $118 million in value terms, driven largely by those Stryker family sales. The CFO filed two small "J-code" transactions in September, a compensation-mechanics category rather than an open-market signal. No insider has bought in the open market over the tracked period. As a disclosure caveat: Schedule 13D/G stakes are event-driven around the 5% threshold, and holders dropping below 5% may not file again. Among institutional holders, JP Morgan Asset Management added nearly 944,000 shares in the period to September 1, and T. Rowe Price added 1.88 million shares to June 30, both bucking the directional trend among the selling names.
Wikipedia attention for Stryker has ticked up, with the retail attention z-score running at 1.2 against the stock's own 90-day history as of September 20. That is a measure of interest, not a revenue signal. None of the company's four alt-data datasets, covering FDA device filings, clinical trials, Wikipedia views and insider clusters, have been measured to lead Stryker's reported figures, so none of them carry predictive weight for the October 30 print.
The valuation has re-rated meaningfully. The price-to-earnings multiple has dropped roughly 2.9 points over the past 30 days to 17.1x, and price-to-book has fallen 0.6 points to 3.6x. Those moves reflect the 15.7% decline in the share price over the month. Peers have been more mixed: MDT fell 4% on the week while ZBH dropped 2.8%, making Stryker's flat-to-slight-gain look relatively resilient. STE and GMED were essentially flat.
The October 30 earnings report is what everything pivots on now. How management characterises the Peripheral Vascular recovery, the pace of cyberattack remediation, and whether organic growth guidance holds inside the 8.3% to 9.3% range will determine whether the current analyst target-cutting cycle has further to run or has run its course.
See the live data behind this article on ORTEX.
Open SYK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
